Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
LifeArc-founded RQ Bio secures £85.5 million to advance long-acting antibody for influenza prevention
-
New boost for personalised rare disease treatments as the Rare Therapies Launch Pad becomes part of LifeArc
-
World-first gene therapy to target devastating rare immune disorder